These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29035117)

  • 1. A Sophism in Vectorology: Turning Harmful Defective Retroviral Vectors into Helpful Replication-Competent Retroviruses Against Cancer.
    Klatzmann D
    Hum Gene Ther; 2017 Nov; 28(11):954-957. PubMed ID: 29035117
    [No Abstract]   [Full Text] [Related]  

  • 2. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines.
    Dalba C; Bellier B; Kasahara N; Klatzmann D
    Mol Ther; 2007 Mar; 15(3):457-66. PubMed ID: 17245356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gendicine: the first commercial gene therapy product.
    Wilson JM
    Hum Gene Ther; 2005 Sep; 16(9):1014-5. PubMed ID: 16149899
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sixth congress of the European Genetic Therapy Group].
    Piechaczyk M
    Bull Cancer; 1998 Dec; 85(12):1061-5. PubMed ID: 9917558
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
    Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
    J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current status of clinical gene therapy.
    Anderson WF
    Hum Gene Ther; 2002 Jul; 13(11):1261-2. PubMed ID: 12162809
    [No Abstract]   [Full Text] [Related]  

  • 7. An alternative approach to medical genetics based on modern evolutionary biology. Part 4: HERVs in cancer.
    Ryan FP
    J R Soc Med; 2009 Nov; 102(11):474-80. PubMed ID: 19875536
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers.
    Peng Z
    Hum Gene Ther; 2005 Sep; 16(9):1016-27. PubMed ID: 16149900
    [No Abstract]   [Full Text] [Related]  

  • 9. Determination of Sequences Required for Human Endogenous Retrovirus K Transduction and Its Recognition by Foreign Retroviral Virions.
    Erlwein O; Sweeney NP; de Leon R; Wills G; Robinson MJ; McClure MO
    J Virol; 2015 Dec; 90(6):3243-6. PubMed ID: 26719267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceuticals and gene vectors opening new avenues in cancer immune therapy.
    Sami H; Ogris M
    Ther Deliv; 2016 Jul; 7(7):419-22. PubMed ID: 27403627
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene therapy applications of viral vectors.
    Lundstrom K
    Technol Cancer Res Treat; 2004 Oct; 3(5):467-77. PubMed ID: 15453812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSV as a vector in vaccine development and gene therapy.
    Marconi P; Argnani R; Epstein AL; Manservigi R
    Adv Exp Med Biol; 2009; 655():118-44. PubMed ID: 20047039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.
    Metzl C; Mischek D; Salmons B; Günzburg WH; Renner M; Portsmouth D
    J Virol; 2006 Jul; 80(14):7070-8. PubMed ID: 16809312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials involving multidrug resistance transcription units in retroviral vectors.
    Deisseroth AB
    Clin Cancer Res; 1999 Jul; 5(7):1607-9. PubMed ID: 10430058
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.
    Packer RJ; Raffel C; Villablanca JG; Tonn JC; Burdach SE; Burger K; LaFond D; McComb JG; Cogen PH; Vezina G; Kapcala LP
    J Neurosurg; 2000 Feb; 92(2):249-54. PubMed ID: 10659011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral vectors: from cancer viruses to therapeutic tools.
    Miller AD
    Hum Gene Ther; 2014 Dec; 25(12):989-94. PubMed ID: 25458252
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvements in gene therapy: averting the immune response to adenoviral vectors.
    Ritter T; Lehmann M; Volk HD
    BioDrugs; 2002; 16(1):3-10. PubMed ID: 11908997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy: progress and predictions.
    Collins M; Thrasher A
    Proc Biol Sci; 2015 Dec; 282(1821):20143003. PubMed ID: 26702034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vectors and strategies for nonviral cancer gene therapy.
    Pahle J; Walther W
    Expert Opin Biol Ther; 2016; 16(4):443-61. PubMed ID: 26761200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.